EP1089731A4 - Zusammensetzungen und verfahren zur behandlung von erhöhtem blutcholesterolspiegel - Google Patents

Zusammensetzungen und verfahren zur behandlung von erhöhtem blutcholesterolspiegel

Info

Publication number
EP1089731A4
EP1089731A4 EP99930451A EP99930451A EP1089731A4 EP 1089731 A4 EP1089731 A4 EP 1089731A4 EP 99930451 A EP99930451 A EP 99930451A EP 99930451 A EP99930451 A EP 99930451A EP 1089731 A4 EP1089731 A4 EP 1089731A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
treating high
high cholesterolemia
cholesterolemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99930451A
Other languages
English (en)
French (fr)
Other versions
EP1089731A1 (de
Inventor
Edward M Scolnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9817167.1A external-priority patent/GB9817167D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1089731A1 publication Critical patent/EP1089731A1/de
Publication of EP1089731A4 publication Critical patent/EP1089731A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP99930451A 1998-06-24 1999-06-21 Zusammensetzungen und verfahren zur behandlung von erhöhtem blutcholesterolspiegel Withdrawn EP1089731A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9052798P 1998-06-24 1998-06-24
US90527P 1998-06-24
GB9817167 1998-08-06
GBGB9817167.1A GB9817167D0 (en) 1998-08-06 1998-08-06 Compositions and methods for treating elevated blood cholesterol
PCT/US1999/013887 WO1999066929A1 (en) 1998-06-24 1999-06-21 Compositions and methods for treating elevated blood cholesterol

Publications (2)

Publication Number Publication Date
EP1089731A1 EP1089731A1 (de) 2001-04-11
EP1089731A4 true EP1089731A4 (de) 2003-06-18

Family

ID=26314174

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99930451A Withdrawn EP1089731A4 (de) 1998-06-24 1999-06-21 Zusammensetzungen und verfahren zur behandlung von erhöhtem blutcholesterolspiegel

Country Status (5)

Country Link
EP (1) EP1089731A4 (de)
JP (1) JP2002518448A (de)
AU (1) AU754767B2 (de)
CA (1) CA2335366A1 (de)
WO (1) WO1999066929A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350453B1 (en) 1999-05-24 2002-02-26 American River Nutrition, Inc. Tocotrienols and geranylgeraniol from Bixa orellana byproducts
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1601668B1 (de) 2003-03-07 2008-08-27 Schering Corporation Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CA2847543C (en) 2003-04-08 2018-05-15 Barrie Tan Annatto extract compositions, including geranyl geraniols and methods of use
WO2010098906A1 (en) * 2009-02-24 2010-09-02 Madeira Therapeutics Liquid statin formulations
WO2010126579A1 (en) * 2009-04-27 2010-11-04 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of statin-induced myopathy
US20150025077A1 (en) * 2012-02-29 2015-01-22 Coyote Pharmaceuticals, Inc. Gga and gga derivatives compositions thereof and methods for treating neurodegenerative diseases including paralysis including them
WO2014055440A1 (en) * 2012-10-01 2014-04-10 Coyote Pharmaceuticals, Inc. Preparation of gga and derivatives thereof and their co-crystallization with urea or thiourea
US9119808B1 (en) 2012-10-08 2015-09-01 Coyote Pharmaceuticals, Inc. Treating neurodegenerative diseases with GGA or a derivative thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2055100A (en) * 1979-07-27 1981-02-25 Sankyo Co Monacolin K derivatives
EP0671170A1 (de) * 1994-03-11 1995-09-13 Bristol-Myers Squibb Company Verwendung von Pravastatin zur Verlangsamung des Fortschreitens der Atherosklerose koronarer Arterien
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
WO1997019091A1 (en) * 1995-11-23 1997-05-29 Laboratori Baldacci S.P.A. Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions
US5691375A (en) * 1994-01-18 1997-11-25 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
JPH1087480A (ja) * 1996-09-13 1998-04-07 Eisai Co Ltd 抗動脈硬化治療剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933165A (en) * 1989-01-18 1990-06-12 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
EP0448697B1 (de) * 1989-10-13 1996-04-10 Neurofit Analoge von vitamin a und ihre verwendung, insbesondere als cytotrophische und cytoprotective substanzen sowie diese substanzen enthaltende arzneimittel
US5639653A (en) * 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
US5763646A (en) * 1997-03-13 1998-06-09 Ranbaxy Laboratories, Ltd. Process for manufacturing simvastatin from lovastatin or mevinolinic acid

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2055100A (en) * 1979-07-27 1981-02-25 Sankyo Co Monacolin K derivatives
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5691375A (en) * 1994-01-18 1997-11-25 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
EP0671170A1 (de) * 1994-03-11 1995-09-13 Bristol-Myers Squibb Company Verwendung von Pravastatin zur Verlangsamung des Fortschreitens der Atherosklerose koronarer Arterien
WO1997019091A1 (en) * 1995-11-23 1997-05-29 Laboratori Baldacci S.P.A. Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions
JPH1087480A (ja) * 1996-09-13 1998-04-07 Eisai Co Ltd 抗動脈硬化治療剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FLINT OLIVER P ET AL: "Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induced myotoxicity in vitro.", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 145, no. 1, 1997, pages 91 - 98, XP002237082, ISSN: 0041-008X *
PATENT ABSTRACTS OF JAPAN vol. 199, no. 809 31 July 1998 (1998-07-31) *
See also references of WO9966929A1 *

Also Published As

Publication number Publication date
CA2335366A1 (en) 1999-12-29
AU4698999A (en) 2000-01-10
JP2002518448A (ja) 2002-06-25
AU754767B2 (en) 2002-11-21
EP1089731A1 (de) 2001-04-11
WO1999066929A1 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
EP1089731A4 (de) Zusammensetzungen und verfahren zur behandlung von erhöhtem blutcholesterolspiegel
EP1446114A4 (de) Zusammensetzungen und verfahren zur behandlung von osteoporose
NO20003096L (no) Sammensetninger og fremgangsmÕter for behandling av ADD
EP1089732A4 (de) Zusammenstellungen und methoden zur behandlung von erhöhtem blutcholesterolspiegel
NO20012916L (no) Sammensetninger og fremgangsmåter for behandling av anorektale forstyrrelser
EP0709467A3 (de) Zusammensetzungen und Verfahren für die Detektion von Chlamydia Trachomatis
ID28728A (id) Komposisi dan proses pengkrepan
PT945132E (pt) Composicao de ibuprofeno
IL132145A0 (en) Methods and compositions for treating inflammatory bowel disease
BR9509200A (pt) Composição de matéria
DE69518844D1 (de) Riechstoffe für wasch- und reinigungsmittelzusammensetzungen
DE69603089D1 (de) Zusammensetzung zur behandlung von mauerwerk
DE69713907D1 (de) Wasserenthärtende Zusammensetzungen und Waschmittelzusammensetzungen
DE69522117D1 (de) Waschmittelzusammensetzung und waschverfahren
BG105437A (en) REFLECTIVELY MODIFIED COMPOSITIONS AND METHODS FOR OBTAINING THEM
FI970534L (fi) Menetelmät ja koostumukset endotoksiinin liittyvien tilojen ennaltaehkäisemiseksi ja hoitamiseksi
ATE212535T1 (de) Tensidzusammensetzungen
ITMI950711A0 (it) Composizione efficace nella rimozione degli asfalteni
PL336349A1 (en) Compositions for and methods for treating and diagnosing the mastocarcinoma
FR2771297B1 (fr) Sonde bicanaliculaire pour le traitement du larmoiement de l'oeil
BR9612283A (pt) Composição para o tratamento de manchas em peças de roupa e métodos de tratamento
NO985385L (no) Bitumensammensetninger og fremgangsmÕte for fremstilling derav
ZA981600B (en) Methods and compositions for treating stickies
FI963868L (fi) Bitumikoostumuksia
DE69939166D1 (de) Wasserenthärtungs- und waschmittelzusammensetzungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010124;LT PAYMENT 20010124;LV PAYMENT 20010124;MK PAYMENT 20010124;RO PAYMENT 20010124;SI PAYMENT 20010124

A4 Supplementary search report drawn up and despatched

Effective date: 20030508

17Q First examination report despatched

Effective date: 20031106

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040317